Business Context and Reporting Period
This Form 8-K is a current report filed by Anthem, Inc. (now Elevance Health, Inc.) on June 9, 2020. The filing serves as a Regulation FD disclosure regarding updated financial guidance provided by company officers during investor meetings.
Key Financial Metrics
The filing does not report historical revenue, profit, cash flow, margins, debt, or liquidity figures for a specific reporting period. Instead, it provides forward-looking per-share earnings guidance for the full year 2020:
- Full Year 2020 Net Income Guidance: Greater than $21.00 per share.
- Unfavorable Items: Approximately $1.30 per share included in the net income guidance.
- Adjusted Net Income Guidance: Greater than $22.30 per share (excluding unfavorable items).
- Earnings Timing: The company expects to generate approximately 70% of its adjusted earnings per share in the first half of the year.
Material Changes
The primary material update is the reaffirmation of the full-year 2020 net income guidance and the specific clarification regarding the timing of earnings generation. The company now explicitly expects 70% of adjusted earnings to be realized in the first half of the year, a detail not previously emphasized in the same manner. No other adjustment items beyond those reported in the first quarter 2020 earnings release are included in this guidance.
Guidance, Outlook, and Risks
Management Commentary: Officers intend to reaffirm the guidance during investor meetings over the weeks following the filing date. The guidance excludes any adjustment items beyond those already reported in Q1 2020.
Risks and Contingencies: The filing includes extensive forward-looking statement disclaimers citing numerous risks that could cause actual results to differ materially from projections. Key risks identified include:
- Impact of public health epidemics and pandemics, specifically COVID-19.
- Trends in healthcare costs, utilization rates, and premium rate adequacy.
- Regulatory changes to the Affordable Care Act (ACA) and legal challenges thereto.
- Litigation outcomes, including the merger agreement dispute with Cigna Corporation.
- Pharmacy benefit management (PBM) compliance and operational risks.
- Substantial outstanding indebtedness and potential downgrades in financial strength ratings.
- Information security breaches and data privacy issues.
Investor Verification Checklist
- Verify the specific nature and magnitude of the $1.30 per share in "net unfavorable items" referenced in the guidance.
- Confirm the status and potential financial impact of the ongoing litigation with Cigna Corporation regarding the merger agreement.
- Monitor the actual first-half earnings realization to see if it aligns with the 70% adjusted EPS projection.
- Review subsequent filings for updates on COVID-19's impact on healthcare utilization and costs.
- Assess the company's liquidity and debt service capabilities given the cited risks regarding substantial indebtedness.